Patents by Inventor Josep Llaveria Cros

Josep Llaveria Cros has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • NEW COMPOUND
    Publication number: 20240043450
    Abstract: The invention relates to novel compounds for use as inhibitors of NLRP3 inflammasome production, wherein such compounds are as defined by compounds of formula (I) and wherein the integers R1, R2 and R3 are defined in the description, and where the compounds may be useful as medicaments, for instance for use in the treatment of a disease or disorder that is associated with NLRP3 inflammasome activity.
    Type: Application
    Filed: September 23, 2021
    Publication date: February 8, 2024
    Inventors: Daniel OEHLRICH, Nina VAN OPDENBOSCH, Michiel Luc Maria VAN GOOL, Dries VAN ROMPAEY, Gary John TRESADERN, Josep LLAVERIA CROS, Mohamed LAMKANFI
  • PYRAZOLO[1,5-D][1,2,4]TRIAZINE-5(4H)-ACETAMIDES AS INHIBITORS OF THE NLRP3 INFLAMMASOME
    Publication number: 20230203044
    Abstract: The invention relates to novel compounds for use as in-hibitors of NLRP3 inflammasone production, wherein such compounds are as defined by compounds of formula (I) and wherein the integers R1, R2 and R3 are defined in the description, and where the compounds may be useful as medicaments, for instance for use in the treatment of a disease or disorder that is associated with NLRP3 inflammasome activity.
    Type: Application
    Filed: April 15, 2021
    Publication date: June 29, 2023
    Inventors: Daniel OEHLRICH, Michiel Luc Maria VAN GOOL, Nina VAN OPDENBOSCH, Mohamed LAMKANFI, Josep LLAVERIA CROS, Carlos Manuel MARTINEZ VITURRO, Dries VAN ROMPAEY
  • Pharmaceutical 6,5 Heterobicyclic Ring Derivatives
    Publication number: 20200399268
    Abstract: The invention relates to 6,5 heterobicyclic ring derivatives of formula (I), processes for preparing them, pharmaceutical compositions containing them and their use for the treatment of inflammatory conditions driven by STING activation, such as, but not confined to, SLE and geographic atrophy.
    Type: Application
    Filed: February 15, 2019
    Publication date: December 24, 2020
    Inventors: Jag Paul Heer, Michal Sarah Hallside, Adam Peter Smalley, Josep Llaveria Cros, Benedicte Lallemand, Martin Alexander Lowe, Xianfu Li, Anthony John Richardson, Robert James Townsend
  • Efficient methods for Z- or cis-selective cross-metathesis
    Patent number: 8598400
    Abstract: The present invention generally relates to methods for performing metathesis reactions, including cross-metathesis reactions. Methods described herein exhibit enhanced activity and stereoselectivity, relative to known methods, and are useful in the synthesis of a large assortment of biologically and therapeutically significant agents.
    Type: Grant
    Filed: February 8, 2011
    Date of Patent: December 3, 2013
    Assignees: Massachusetts Institute of Technology, Trustees of Boston College
    Inventors: Amir H. Hoveyda, Simon J. Meek, Robert V. O'Brien, Josep Llaveria Cros, Richard R. Schrock
  • Efficient methods for Z- or cis-selective cross-metathesis
    Patent number: 8552242
    Abstract: The present invention generally relates to methods for performing metathesis reactions, including cross-metathesis reactions. Methods described herein exhibit enhanced activity and stereoselectivity, relative to known methods, and are useful in the synthesis of a large assortment of biologically and therapeutically significant agents.
    Type: Grant
    Filed: February 8, 2011
    Date of Patent: October 8, 2013
    Assignees: Massachusetts Institute of Technology, Trustees of Boston College
    Inventors: Amir H. Hoveyda, Simon J. Meek, Robert V. O'Brien, Josep Llaveria Cros, Richard R. Schrock
  • EFFICIENT METHODS FOR Z- OR CIS-SELECTIVE CROSS-METATHESIS
    Publication number: 20110245477
    Abstract: The present invention generally relates to methods for performing metathesis reactions, including cross-metathesis reactions. Methods described herein exhibit enhanced activity and stereoselectivity, relative to known methods, and are useful in the synthesis of a large assortment of biologically and therapeutically significant agents.
    Type: Application
    Filed: February 8, 2011
    Publication date: October 6, 2011
    Applicants: Trustees of Boston College, Massachusetts Institute of Technology
    Inventors: Amir H. Hoveyda, Simon J. Meek, Robert V. O'Brien, Josep Llaveria Cros, Richard R. Schrock